IR.ADVAXIS.COM

Overview :: Advaxis, Inc. (ADXS)

Advaxis, Inc. (NASDAQ: ADXS). Either directly or through strategic collaborations with recognized cancer centers of excellence. Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial. Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer. Advaxis Analyst and Investor Day in New York City. Gregory T. Mayes. 305 College Rd East. Princeton, NJ 08540. T: 609-452-9813 ext 102. View Detailed Stock Info.

http://ir.advaxis.com/

OVERVIEW OF ir.advaxis.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

4

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR IR.ADVAXIS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

April

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Wednesday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.3 out of 5 with 12 reviews

5 star

7

4 star

2

3 star

3

2 star

0

1 star

0

Hey there! Start your review of ir.advaxis.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

1.1 seconds

FAVICON PREVIEW

16x16
32x32

CONTACTS AT IR.ADVAXIS.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

4

SSL

EXTERNAL LINKS

31

SITE IP

54.152.98.57

LOAD TIME

1.055 sec

SCORE

6.2

PAGE TITLE

Overview :: Advaxis, Inc. (ADXS) | ir.advaxis.com Reviews

<META> DESCRIPTION

Advaxis, Inc. (NASDAQ: ADXS). Either directly or through strategic collaborations with recognized cancer centers of excellence. Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial. Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer. Advaxis Analyst and Investor Day in New York City. Gregory T. Mayes. 305 College Rd East. Princeton, NJ 08540. T: 609-452-9813 ext 102. View Detailed Stock Info.

<META> KEYWORDS

1 advaxis inc

2 about us

3 overview

4 management team

5 board of directors

6 partners

7 existing partners

8 technology

9 lm technology™

10 scientific publications

CONTENT

Page content here

KEYWORDS ON PAGE

advaxis inc,about us,overview,management team,board of directors,partners,existing partners,technology,lm technology™,scientific publications,intellectual property,scientific presentations,pipeline,adxs hpv,adxs psa,adxs her2,news,press releases,investors

SERVER

Apache/2.4.12 (Ubuntu)

POWERED BY

PHP/5.5.9-1ubuntu4.11

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Overview :: Advaxis, Inc. (ADXS) | ir.advaxis.com Reviews

https://ir.advaxis.com

Advaxis, Inc. (NASDAQ: ADXS). Either directly or through strategic collaborations with recognized cancer centers of excellence. Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial. Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer. Advaxis Analyst and Investor Day in New York City. Gregory T. Mayes. 305 College Rd East. Princeton, NJ 08540. T: 609-452-9813 ext 102. View Detailed Stock Info.

INTERNAL PAGES

ir.advaxis.com

1

Press Releases :: Advaxis, Inc. (ADXS)

http://ir.advaxis.com/press-releases/detail/1173/advaxiss-scientific-founder-to-present-on-adxs-her2-at-world-congress-on-breast-cancer-2015

Advaxis's Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015. July 29, 2015. PRINCETON, N.J., July 29, 2015 (GLOBE NEWSWIRE) - Advaxis, Inc. Based cancer immunotherapy for breast cancer" on Tuesday, August 4 at 9:00 am BST, at the 2015 World Congress on Breast Cancer in Birmingham, UK. I've dedicated over 20 years of work to the application of Listeria monocytogenes. Technology immunotherapies have been well-tolerated and have demonstrated anti-tumor activity, including pr...

2

Press Releases :: Advaxis, Inc. (ADXS)

http://ir.advaxis.com/press-releases/detail/1175/advaxis-appoints-tom-ridge-americas-first-secretary-of-homeland-security-and-43rd-governor-of-pennsylvania-to-board-of-directors

Advaxis Appoints Tom Ridge, America's First Secretary of Homeland Security and 43rd Governor of Pennsylvania, to Board of Directors. August 13, 2015. PRINCETON, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) - Advaxis, Inc. NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced the appointment of The Honorable Tom Ridge, the first Secretary of the U.S. Department of Homeland Security and 43. Governor of Pennsylvania, to the Company's Board of Directors. Gov Ridge holds a ...

3

Press Releases :: Advaxis, Inc. (ADXS)

http://ir.advaxis.com/press-releases/detail/744/advaxis-and-merck-form-collaboration-to-evaluate-investigational-combination-of-two-novel-immunotherapy-candidates-for-advanced-prostate-cancer

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer. August 25, 2014. PRINCETON, N.J., Aug. 25, 2014 (GLOBE NEWSWIRE) - Advaxis, Inc. Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm.

4

Press Releases :: Advaxis, Inc. (ADXS)

http://ir.advaxis.com/press-releases/detail/1024/advaxis-forms-clinical-trial-collaboration-with-incyte-to-evaluate-investigational-combination-of-two-novel-cancer-immunotherapies-for-early-stage-cervical-cancer

Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer. February 11, 2015. PRINCETON, N.J., Feb. 11, 2015 (GLOBE NEWSWIRE) - Advaxis, Inc. Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm. LLO immunotherapy candidate, ADXS...

UPGRADE TO PREMIUM TO VIEW 0 MORE

TOTAL PAGES IN THIS WEBSITE

4

LINKS TO THIS WEBSITE

advaxis.com

PARTNERS - Advaxis

http://www.advaxis.com/partners

Advaxis is actively seeking commercialization partners for the license and development of its proprietary investigational. Advaxis has created more than 20 distinct immunotherapy candidates based on its proprietary platform that are available for partnering in anti-PD-1 combination therapy, recurrent cervical cancer, HPV-associated head and neck cancer, HPV-associated anal cancer, prostate cancer, HER2 expressing tumors, and others. Interested parties may contact:. Gregory T. Mayes. 305 College Rd East.

advaxis.com

IN THE NEWS - Advaxis

http://www.advaxis.com/news/in-the-news

Advaxis Recognized by Farrah Fawcett Foundation in Huffington Post. September 14th, 2015. Advaxis featured in NJBIZ. January 13th, 2014. Advaxis Cancer Immunotherapy Featured on ABC News. November 21st, 2013. Advaxis canine trial featured on Arise News. November 21st, 2013.

advaxis.com

PRESS RELEASES - Advaxis

http://www.advaxis.com/investor-relations/press-releases

advaxis.com

ADXS-PSA - Advaxis

http://www.advaxis.com/clinical-pipeline/adxs-psa

ADXS-PSA is under investigation for targeting the prostate-specific antigen (PSA) associated with prostate cancer. ADXS-PSA is in clinical development both as a monotherapy and in combination with immune checkpoint inhibitors for the treatments of metastatic castration-resistant prostate cancer (mCRPC). ADXS-PSA is being evaluated in a Phase 1/2 study of ADXS-PSA as a monotherapy and in combination with PD-1 checkpoint inhibitor KEYTRUDA.

advaxis.com

ADXS-HER2 - Advaxis

http://www.advaxis.com/clinical-pipeline/adxs-her2

Advaxis is developing ADXS-HER2 to target human epidermal growth factor receptor 2 (HER2) expressing cancers. HER2 is expressed in certain solid-tumor cancers, including breast, gastric, esophageal and osteosarcoma. ADXS-HER2 has received orphan drug designation from the FDA and EMA for the treatment of osteosarcoma. ADXS-HER2 is being evaluated in a first-in-human Phase 1b dose-escalation clinical study for the treatment of patients with metastatic HER2 expressing solid tumors. The dose escalation p...

advaxis.com

PRESS RELEASES - Advaxis

http://www.advaxis.com/news/press-releases

UPGRADE TO PREMIUM TO VIEW 25 MORE

TOTAL LINKS TO THIS WEBSITE

31

SOCIAL ENGAGEMENT

advaxisinc

Advaxis

OTHER SITES

ir.adoltelemed.com

American Doctors Online, Inc.

ADOL - American Doctors online: Accelerating Telemedicine Delivery. Paul I. Bulat, MD Chairman and Founder. Paul Fredette - Chief Technology Officer. 200 Mill Road Suite 350A Fairhaven, MA 02719 866.539.7379. Jun 30, 2015. Sign up for email alerts. Be the first to receive breaking news. Paul I. Bulat, M.D., MHI, FACEP. Chairman of the Board, Interim Chief Executive Officer and Chief Innovation Officer. Paul H. Fredette. Paul I. Bulat, M.D., MHI, FACEP. Dr Bulat is Board Certified in Emergency Medicine an...

ir.adrianvintu.com

Istoria Românilor

DEX pentru Windows Phone. User Manager Dictionary (UDM). DEX pentru Windows Phone. DEX este un dictionar explicativ roman pentru platforma Windows Phone. Aplicatia este sora DEX-ului pentru Android, fiind insa in versiunea 1.6 deocamdata, deci oferind facilitati mai putin numeroase decat sora ei mai mare :). Printre caracteristicile sale se afla:. Peste 500.000 de inregistrari in baza de date. Definitiile pot fi distribuite pe email. Preferinte legate de interfata pot fi setate in meniul Preferinte.

ir.adrianvintu.net

Istoria Românilor

DEX pentru Windows Phone. User Manager Dictionary (UDM). DEX pentru Windows Phone. DEX este un dictionar explicativ roman pentru platforma Windows Phone. Aplicatia este sora DEX-ului pentru Android, fiind insa in versiunea 1.6 deocamdata, deci oferind facilitati mai putin numeroase decat sora ei mai mare :). Printre caracteristicile sale se afla:. Peste 500.000 de inregistrari in baza de date. Definitiile pot fi distribuite pe email. Preferinte legate de interfata pot fi setate in meniul Preferinte.

ir.advanced-energy.com

Corporate Profile

DESIGN YOUR PV SYSTEM. AE Design (for UL Products). AE Design (for international use). AE 3TL HORIZONTAL MOUNTING KIT. AE REMOTE PV TIE. MDX SERIES 500 W. MDX 1 kW and 1.5 kW. PDX MID-FREQUENCY POWER SUPPLIES. CRYSTAL AC POWER SUPPLY. PARAMOUNT RF POWER-DELIVERY SYSTEMS. APEX RF POWER-DELIVERY SYSTEMS. HFV VARIABLE FREQUENCY GENERATORS. CESAR RF POWER SUPPLIES. OVATION VHF POWER-DELIVERY SYSTEMS. SEKIDENKO MXE HIGH-SPEED PYROMETER. SEKIDENKO OR4000 SERIES OFTS and EMISSOMETERS. 160;at 8:00 am ET.

ir.advanceddisposal.com

Advanced Disposal Services - Investors - Overview

Please Read and Agree to the Following Before Proceeding. Disposal and Recycling Services. Disposal and Recycling Services. Life Cycle of Trash. Material Recovery Facility (MRF) Diagram. Recycling Facts and Trivia. Recycling at Home and Work. Recycling Tips and Trivia. Recycling at Home and Work. Our business is your business. We’re committed to providing timely, transparent information to our investors every step of the way. Our business is your business. 302,000 commercial and industrial customers.

ir.advaxis.com

Overview :: Advaxis, Inc. (ADXS)

Advaxis, Inc. (NASDAQ: ADXS). Either directly or through strategic collaborations with recognized cancer centers of excellence. Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial. Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer. Advaxis Analyst and Investor Day in New York City. Gregory T. Mayes. 305 College Rd East. Princeton, NJ 08540. T: 609-452-9813 ext 102. View Detailed Stock Info.

ir.adways.net

株式会社アドウェイズIR情報

ir.aecrealty.com

Associated Estates Realty Corp - Investor Relations

Aug 6, 2015. AEC is dual listed and trades on NASDAQ. Quotes delayed at least 20 minutes. Information provided by eSignal. Wells Fargo Shareowner Services. 1110 Centre Pointe Curve Suite 101. Mendota Heights, MN 55120-4100. The above transfer agent contact information is intended for individual investors who are interested in enrolling in our Dividend Reinvestment Plan in order to buy, sell or transfer AEC stock.

ir.aegerion.com

Aegerion Pharmaceuticals, Inc. - Overview

4:00 PM ET on Aug 7, 2015. Delayed at least 20 minutes. Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Press Releases View all. Aug 5, 2015. Aegerion Pharmaceuticals Announces Second Quarter 2015 Financial Results. Jul 27, 2015. Aegerion Pharmaceuticals Announces Leadership Changes to Support the Next Stage of Growth. Jul 13, 2015. Aug 7, 2015 at 4:00 PM ET.

ir.aegleabio.com

Aeglea Biotherapeutics - Investors - Investors

Patients and Caregivers Overview. As of 01/11/17 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. Aeglea BioTherapeutics to Present at BMO Capital Markets Prescription for Success Healthcare Conference. AUSTIN, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) - Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer,. There are currently no events scheduled.

ir.aeroflot.com

Shareholders and Investors | Aeroflot

Traffic and Financial Highlights. General Meeting of Shareholders. Traffic and Financial Highlights. General Meeting of Shareholders. Board of Directors Committees. Internal Audit and Revision Committee. One airline in Russia. Developing a global hub at Sheremetyevo airport. Aeroflot the best airline. One of the youngest fleets. In the industry globally. Aeroflot Group Announces Operating Results for November 2016. Aeroflot Announces 9M 2016 IFRS Financial Results. Download Annual Report 2015.